Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

S1200000

Spironolactone

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

4-Pregnen-21-oic acid-17α-ol-3-one-7α-thiol γ-lactone 7-acetate, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C24H32O4S
Número CAS:
52-01-7
Peso molecular:
416.57
Número MDL:
MFCD00082250
Código UNSPSC:
41116107
ID de substância PubChem:
329824467
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

spironolactone

fabricante/nome comercial

EDQM

pf

207-208 °C (lit.)

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

cadeia de caracteres SMILES

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

chave InChI

LXMSZDCAJNLERA-ZHYRCANASA-N

Informações sobre genes

human ... NR3C2(4306)

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Spironolactone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Pictogramas

Health hazard
GHS08

Palavra indicadora

Danger

Frases de perigo

H351,H360FD,H373

Classificações de perigo

Carc. 2 - Repr. 1B - STOT RE 2

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 6

1 of 6

Midostaurin hydrate ≥98% (HPLC), solid

Sigma-Aldrich

M1323

Midostaurin hydrate

Aldosterone-2,2,4,6,6,21,21-d7 ≥98 atom % D (based on d7), ≥98% (CP)

Sigma-Aldrich

706035

Aldosterone-2,2,4,6,6,21,21-d7

Benazepril hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

B0935

Benazepril hydrochloride

Aldosterone ≥95% (HPLC)

Sigma-Aldrich

A9477

Aldosterone

Mifepristone ≥98%

Sigma-Aldrich

M8046

Mifepristone

Everolimus ≥95% (HPLC)

Sigma-Aldrich

SML2282

Everolimus

Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Christopher J A Neil et al.
JAMA, 310(2), 204-204 (2013-07-11)
D A Andreev et al.
Kardiologiia, 53(3), 94-96 (2013-04-04)
It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors. The patient (75 years old) at the decompensation of chronic heart failure in
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Lars H Lund et al.
JAMA, 310(2), 205-205 (2013-07-11)
Adam D Karns et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(3), 186-192 (2013-03-06)
Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension. Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland. In this study, the efficacy
Prescrire international, 22(139), 148-149 (2013-07-20)
Still no randomised controlled trials versus spironolactone, but a prematurely terminated placebo-controlled trial with 2737 patients.
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica